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serum and that PPARalpha is a limiting factor in serum Vnn1 production. Functional PPRE sites
are identiﬁed in the Vnn1 promoter. These results indicate that serum Vnn1 might be a reliable
reporter of PPARalpha activity in liver.
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Pantetheinase has been discovered a long time ago [1] but its
biological function remains poorly understood. This enzyme
hydrolyzes pantetheine to pantothenic acid (vitamin B5) and the
amino-thiol cysteamine [2]. Cystamine, the oxidized form of cyste-
amine, is thought to act by engaging mixed disulﬁdes with cyste-
ines regulating the function of target enzymes [3,4]. In mouse,
two pantetheinase isoforms Vnn1 and Vnn3 are encoded by Vanin
(Vnn) genes [5]. The Vnn3 isoform is preferentially expressed by
hematopoietic cell subsets [5] and contributes to the resistance
to malaria infection [6]. The Vnn1 isoform is a GPI-anchored ecto-
enzyme [7] and its expression is developmentally regulated [8,9].
In adult tissues, Vnn1 is heterogeneously expressed by epithelial
tissues [10] and its expression level is modulated by stress
[11,12]. Microarray analyses have shown that PPARa activation
lead to upregulated Vnn1 gene expression [13,14]. Using Vnn1
deﬁcient mice, we showed that Vnn1 regulates gut inﬂammation
[3,15]. It also exerts a cytoprotective effect on islet beta cells andits deﬁciency exacerbates type 1 diabetes in NOD mice [16]. Vnn
molecules are candidate markers of pathological situations in
human [17].
A pantetheinase activity has been detected in serum [18] but its
molecular nature, origin and regulation are unknown. Given the
contribution of pantetheinase activity to various pathological dis-
orders, it is of interest to investigate the regulation of serum pan-
tetheinase production. To track Vanin/pantetheinase production in
tissues and body ﬂuids, we designed a novel pantetheinase sub-
strate and ELISA. Here, we show that liver contributes to serum
Vnn1 (sVnn1) production and that PPARa is absolutely required
for this process. These results position Vnn1 as a novel reporter
of PPARa-regulated liver response to a metabolic challenge.2. Materials and methods
2.1. Mice
C57BL/6 mice were bred, fed on normal chow diet and main-
tained under speciﬁc pathogen-free (SPF) conditions at the animal
facility of the CIML. Experiments were conducted in accordance
with institutional guidelines for animal care and use. The PPARa-
deﬁcient mice provided by FJ Gonzalez were backcrossed on the
C57BL/6 background [19–21] and maintained at the Pasteur
S. Rommelaere et al. / FEBS Letters 587 (2013) 3742–3748 3743Institute (INSERM, Lille). Fenoﬁbrate administration was per-
formed by gavage (200 mg/kg). All experiments were done on fe-
male mice.
2.2. Subjects
Blood samples were collected after an overnight fast from 22
healthy adult normal-weight subjects within the Department of
Nutrition, Metabolic Diseases and Endocrinology, CHU La Timone,
APHM, Marseille, France (Pr R. Valéro). Sera were immediately
separated by centrifugation (3500 rpm; 15 min; 4 C) and stored
at 80 C. This study was conducted in accordance with the Dec-
laration of Helsinki and approved by the Ethics Committee of
Marseille. Written informed consent was obtained from all
subjects.
2.3. Pantetheinase substrate
Synthesis of the pantetheine analogue pantothenate-4-nitroan-
ilide (pPNa) (2) was performed according to Fig. 1 with the help of
F Pinnen, (University of Chieti, Italy). As described [22], precursor 1
was coupled with D-pantolactone to give compound 2 in good
yield. Pantetheine analogue 2 was fully characterized (2): 1H
NMR (DMSO-d6) d = 0.74 (3H, s, CH3), 0.77 (3H, s, CH3), 2.56 (2H,
m, CH2CO), 3.11–3.25 (2H, m, CH2OH), 3.44 (2H, m, CH2NH), 3.69
(1H, d, CHOH), 4.46 (1H, t, CH2OH), 5.36 (1H, d, CHOH), 7.81 and
8.20 (5H, m, NH and aromatics), 10.55 (1H, s, NH); 13C NMR
(DMSO-d6) d = 20.89 (CH3), 21.62 (CH3), 35.08 (CH2CO), 37.07 (CH2-
NH), 39.34 (C(CH3)2), 68.64 (CH2OH), 75.62 (CHOH), 119.37,
125.66, 142.73, 145.96 (aromatics), 171.35 and 173.70 (2  CO).
The S-pantetheine-3-pyruvate substrate was synthesized as previ-
ously described [2] starting with pantethine (Sigma–Aldrich USA).
Puriﬁed pig kidney pantetheinase (16.5 nM) used for validation
[23] was added to 10 mM K-phosphate buffer, pH 8.0 containingFig. 1. (A) Scheme of synthesis of the pPNa pantetheinase substrate in the following
conditions (a) D-pantolactone, 80 C for 20 h then rt for 72 h. (B) Time resolved
difference steady state spectra: pig pantetheinase (16–20 nM) was added to
substrates (100 lM) in phosphate buffer 10 mM pH 8.0; spectra are relative to
substrate absorption.100–500 lM pantetheine analogues and the increase in absor-
bance at different wavelengths was registered with time at 25 C.
2.4. Pantetheinase activity
Serum pantetheinase activity was measured as follows: 20 ll
pre-reduced (50 lM 2-beta mercaptoethanol, 10 min) serum were
added to 10 ll of pPNA (0.2 mg/ml) in sodium phosphate buffer
10 mM, pH 8.0 and the increase in absorbance (405 nm) measured
(e = 12144 M1 cm1). We also used the pantothenate-7-amino-4-
methylcoumarin (pAMC) substrate (KaïronKem, Marseille, France)
as described [24]. For tissues, activity was measured on enriched
membrane fractions. Cultured cells (4  105) were lysed in 100 ll
of PBS, 0.1% DOC in the presence of protease inhibitors (Roche).
After centrifugation at 10000g for 10 min, protein concentration
was measured in the supernatants using the BCA reagent (Pierce
Thermo Scientiﬁc). Activity was measured by incubating 20–
50 lg of total proteins or 20 ll of serum in a ﬁnal volume of
200 ll phosphate buffer pH 8, containing 0.01% BSA, 1% DMSO,
0.0025% Brij 35, 500 lM DTT for 10 min at rt before addition of
20 lM pAMC. When indicated, sera were ultracentrifuged for
45 min at 50000 g. The appearance of AMC was followed during
the ﬁrst 60 min of the reaction by ﬂuorescence at 355 nM using a
ﬂuorimeter (Wallac Victor, Perkin Elmer).
2.5. Antibodies, immunostaining and ELISA
Two anti-mouse Vnn1 mAbs (407, rat IgG1,j; and 24B1, rat
IgG2a,j) recognizing distinct epitopes of the Vnn1 catalytic do-
main were used to set up the ELISA. The 24B1 was produced by
immunizing rats with the Vnn1-transfected MTE1D cell line as
in [7]. The anti-Vanin-1 antiserum (AS90) was obtained by subcu-
taneous immunization of a rabbit with the Vanin-1-speciﬁc YAP-
DSPRVFHYDRKTQEGK peptide coupled to a KLH (Sigma
chemicals) carrier protein in Freund adjuvant and immunopuri-
ﬁed on peptide-coated beads. The anti-human VNN1 mAbs were
produced either after immunization with VNN1 MTE1D cell trans-
fectants in rats (34G7, rat IgG2a,j) or intra peritoneal injection of
10 lg of recombinant VNN1 molecule (SINO) in CFA in Vnn1-deﬁ-
cient mice (6E3.5, mouse IgG1,j). This recombinant molecule was
also used to calibrate the human VNN1 ELISA. For the ELISA, puri-
ﬁed mAb (24B1 for mouse and 6E3.5 for human) were coated on
plates, whereas the other (407 for mouse and 34G7 for human)
was biotinylated (Pierce) and revealed with a strepatividin–per-
oxidase probe (Sigma). The CK19 goat polyclonal antiserum was
purchased from Santa Cruz Biotechnology. The 735 mAb recogniz-
ing reticular ﬁbroblasts was previously described [7]. Tissue ly-
sates, western blots and immunohistochemistry were performed
as described [15]. Immunoprecipitation was performed using
the 407 and 24B1 anti-Vnn1 mAbs coupled to Protein G-sephar-
ose beads and the pre-adsorbed AS90 anti-Vnn1 serum used for
the western blot, revealed by an anti-rabbit TrueBlot reagent
(eBioscience).
2.6. Plasmids
The pVnn1-luciferase and Vnn1 plasmids were previously de-
scribed [5,11]. The candidate PPRE sites identiﬁed by bioinformat-
ics analysis (Biobase P-match software, positions 2001/1989
and 1759/1747 starting from the ATG site) were mutated in the
AGGTCA consensus site by replacing the G by T nucleotides using
the Quickchange site-directed mutagenesis Kit (Agilent). The
V1dCr mutant construct was generated by introducing a G659?C
point mutation in the TGT codon leading to the Cys213?Ser mod-
iﬁcation. MTE1D cells were transfected with either the control or
mutated version of Vanin-1, sorted by ﬂow cytometry for
Table 1
Pantetheinase activity and immunoreactivity of Vnn1 dCr variant.
Test mAb MTE1D cell lines expressing
Control Vnn1 Vnn1 dCr
Enzymatic activity (pAMC) 6 741 53
RFI 407 2 640 580
24B1 7 815 nt
MTE1D cells transfected with control, Vnn1 or Vnn1 dCr plasmids were tested for
pantetheinase activity (pAMC substrate) and Vnn1 expression by ﬂow cytometry
(RFI).
3744 S. Rommelaere et al. / FEBS Letters 587 (2013) 3742–3748homogeneous cell surface expression (FACS Aria, BD Biosciences)
using the anti-Vanin-1 407 mAb. The mutated versions of Vnn1
were generated as described in Supplementary data. The mouse
RXRa and PPARa cDNA was inserted in the pSG5 vector (Addgene).
For hydrodynamic injection, 50 lg pLIVE plasmids (Mirus Bio LCC)
were injected in the tail vein of Vnn1-deﬁcient mice using the
hydrodynamic injection protocol [25]. Sera and livers were col-
lected 3 days later and assayed for Vnn1 ELISA and pantetheinase
activity using the AMC substrate.
2.7. Cells and luciferase reporter assays
MTE1D cells [7] were transfected with Vanin-1 (MTE1DVH4) or
a mutant form of Vanin-1 (MTE1DV1dCR) cDNAs and analyzed by
ﬂow cytometry (FACS Canto II analyzer, Becton Dickinson). The
AML12 hepatocyte and Caco-2 cell lines were purchased from
ATCC. These cells (105/well) were transiently transfected with
combinations of plasmids (normalized quantity of DNA: 0.8 lg)
using Lipofectamine™ 2000 or Lipofectamine LTX (Life Technolo-
gies). When indicated, cells were stimulated with WY-14643 (Sig-
ma) (50 lM) for 24 h. 48 h post transfection, luminescence was
detected using the Dual-Luciferase reporter assay (Promega).
2.8. Bioinformatics analysis
PPARa ChIP-seq data were from [26]. Raw ChIP-seq data were
downloaded from the Gene Expression Omnibus database
(GSM864671) and wig ﬁle was generated using MACS [27].500
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3.1. Synthesis of a new pantetheinase substrate
Former pantetheinase substrates were previously described,
but with poor sensitivity (SPP) [10] or relatively restricted speci-
ﬁcity (pAMC) for the VNN1 isoform [24]. Several pantetheinase
isoforms exist in mouse and man [5]. To detect all pantetheinase
activity in various tissues and body ﬂuid, a new chromogenic
substrate (pPNa pantothenate-p-nitroanilide) was synthesized
(Fig. 1A). Results in Fig. 1B show time-resolved difference spectra
obtained by using puriﬁed pig pantetheinase and tested as
described [23]. This analysis showed the transition between two
chemical species with an isosbestic point at 344 nm. Data ﬁtted
to time integrated Michaelis Menten equation
[t = KM/Vmax ln(S0/S) + (S0  S)/Vmax] revealed a mixed zero and
ﬁrst order dependence: ﬁt was determined at 387 nm using anAMC
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parameters were: KM = 4.0 ± 0.4 (lM), kcat = 0.9 s1, kcat/
KM = 2.25 105 M1 s1. These results suggest that the enzymatic
afﬁnity towards pPNa is improved with respect to the previously
described S-pantetheine 3-pyruvate (SPP) (KM pPNa = 4 lM; KM
SPP = 28 lM) [2]; furthermore the new colorimetric detection is
more sensitive than the SPP substrate due to a higher extinction
coefﬁcient and the absence of protein absorption overlapping
(kmax = 387 nm).
3.2. Vnn1 contributes to serum pantetheinase activity
Using the pPNa and the pAMC [24] substrates, we detected
pantetheinase activity in the serum of adult C57BL/6 mice
(Fig. 2A). In Vnn1-deﬁcient mice, this activity was reduced by
30% using the pPNa substrate and poorly detectable using the
pAMC substrate. To conﬁrm the presence of a soluble form of Va-
nin-1, we developed an anti-Vnn1 ELISA using the 407/24B1 mAb
pair. These mAbs speciﬁcally recognize Vanin-1 on cell transfec-
tants (Table 1) and more speciﬁcally two independent epitopes
of the catalytic domain (data not shown). As shown in Fig. 2B,
we could detect Vanin-1 in the serum of wild type but not Va-
nin-1 deﬁcient mice. The residual activity detected in Vnn1-deﬁ-
cient mice by the pPNa but not the pAMC substrate is likely
contributed by Vnn3. The Vnn3 isoform has no transmembraneA
A
U
sl
op
e
50
40
30
20
10
0
pFLAGpFLAG Vnn1 Vnn1 dCr
0.15
0.2
0.1
0.05
0
Vnn1 Vnn1 dCr Vnn1 Vnn1 dCr
sl
op
e
0.3
0.4
0.2
0.1
0
A
U
800
600
400
200
0
activity ELISA
liverD
activity
**
**
C
WTKO
Fig. 3. Liver contributes to sVnn1 production. (A) Immunohistochemistry on frozen liver
(Alexa 546-coupled secondary antibody) (16). (B) Combined staining (16) using Vn
CLV = centrolobular vein). (C) Quantiﬁcation of enzymatic activity (left panel, pAMC sub
transfected with control (pFLAG), Vnn1 or Vnn1 dCr plasmids (Mean and S.D. of duplic
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two independent experiments).segment and can be secreted in vitro [5]. Due to the lack of
Vnn3-speciﬁc reagents, we were unable to formally test this
hypothesis in vivo. In following experiments, we focused exclu-
sively on Vnn1 activity and used the more speciﬁc and sensitive
pAMC substrate.
Since Vnn1 has been described as a GPI-anchored membrane
ectoenzyme, we explored whether the pantetheinase activity was
found in a soluble or membrane-bound form in the serum. We har-
vested plasma from control and Vnn1-deﬁcient mice and removed
cells and membrane particles by ultracentrifugation. As seen in
Fig. 2C, all the activity detected by either the pAMC substrate is
exclusively present in the supernatant. We then analyzed the
molecular weight of the soluble form by immunoprecipitation
and western blotting with a Vnn1-speciﬁc antiserum (AS90). As
seen in Fig. 2D, the soluble Vnn1 isoform has the same molecular
weight as that of the membrane bound isoform immunoprecipi-
tated from the MTE1DVH4 Vanin-1 cell transfectant.
We wished to extend results obtained in mouse to human.
Through the development of a novel anti-VNN1 ELISA, we docu-
ment the presence of the VNN1 isoform in human serum
(Fig. 2E) and could correlate the amount of VNN1 protein with
the enzymatic activity detected by the pAMC substrate. However
some sera with high activity give no signal using the ELISA suggest-
ing either the existence of a protein polymorphism or the contribu-
tion of other VNN isoforms to the activity. We also comparedCK19
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Fig. 4. PPARa regulates Vnn1 expression. Quantiﬁcation of Vnn1 by ELISA (A and C) or pantetheinase activity using the pAMC and pPNa substrates (B and C) in the serum of
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in activity were not signiﬁcant under these conditions (data not
shown).
3.3. Liver produces serum Vnn1
Vnn1 is expressed by several epithelial tissues. As shown in
Fig. 3A, immunohistochemistry showed Vnn1 expression on con-
trol C57BL/6 but not Vnn1-deﬁcient mouse hepatocytes. A larger
view combined with costaining using the CK19 marker of biliary
ducts shows that Vnn1 is predominantly expressed by centrolobu-
lar hepatocytes (Fig. 3B). We then tested whether Vnn1 could be
secreted by hepatocytes. As a control we prepared a mutant
Vnn1 isoform carrying a mutation of cysteine 213 (dCr) predicted
to be in the catalytic site of the enzyme by bioinformatics analysis
[28]. As indicated in Table 1, the dCr variant is normally expressed
by transfected cells but its activity is impaired. We then transfec-
ted control or dCr variant cDNAs in the AML12 hepatocyte cell line,
and could detect Vnn1 in the supernatant of transfected cells
(Fig. 3C). In contrast, the enzymatic activity could only be recov-
ered from cells transfected with the catalytically active isoform.
To test the ability of hepatocytes to secrete Vnn1 in vivo, we
administered Vnn1-containing pLIVE plasmids by hydrodynamic
injection in the tail vein of Vnn1-deﬁcient mice, thereby allowing
transient in situ transfection of hepatocytes [25]. Three days fol-
lowing injection of control or dCR Vnn1 plasmids, we quantiﬁed
the level of Vnn1 protein and pantetheinase activity in the liver
and the serum (Fig. 3D). No activity was detected in other organs
such as lung or kidney (Supplementary data, Figs. S1 and S2).
While a comparable amount of Vnn1 protein was produced, serum
pantetheinase activity was only restored in mice receiving control
but not dCr Vnn1. Altogether these results show that the liver can
produce sVnn1.
3.4. PPARa controls Vnn1 expression by hepatocytes and its secretion
in serum
A previous report documented a lack of Vnn1 transcripts in the
liver of PPARa-deﬁcient mice even after stimulation with various
agonists [29]. PPARa is a transcription factor involved in the liver
response to fasting [30,31]. As shown in Fig. 4A–C, sVnn1 and enzy-
matic activity using the pAMC substrate are enhanced in fasted or
fenoﬁbrate-treated control mice but barely detectable in PPARa-
deﬁcient in all conditions. In contrast, using the pPNa substrate,
the basal level of pantetheinase activity is comparable in fed con-
trol and PPARa-deﬁcient mice (Fig. 4B). After fasting, only control
mice show a signiﬁcant enhancement of enzymatic activity. The
production of hepatic enzymes such as ALT is unaffected excluding
a non-speciﬁc release due to cell lysis (not shown). Furthermore,
the vnn1 transcript (Fig. 4D) as well as known PPARa target gene
(acca1b, ehhadh) transcripts are strongly enhanced by fenoﬁbrate
administration in control but not PPARa-deﬁcient mice. The level
of Vnn3 transcription is unaffected by fenoﬁbrate treatment.
Accordingly, fenoﬁbrate provokes a major enhancement of the
amount of the 70 kD vnn1 protein in the liver of control and not
Vnn1-deﬁcient mice (Fig. 4E), comparable to that detected in ser-
um. This increase is also documented by ELISA and enzymatic as-
say in serum or liver membrane and soluble fractions by ELISA
(Supplementary data, Fig. S3).
To conﬁrm PPARa contribution to the regulation of the vnn1
gene, we performed a bioinformatics search for PPARa occupancy
sites detected by CHIP sequencing data stored in the GEO database
[26]. Results using MACS and FindPeaks softwares pinpointed two
candidate regions, upstream of the vnn1 gene (Fig. 4F). We focused
on the proximal candidate site and designed reporter assays using
constructs containing triplicated PPRE sites or various fractions ofthe Vnn1 promoter upstream of the luciferase gene. The constructs
were cotransfected in Caco2 cells (or AML12 cells, not shown) with
plasmids coding for mouse PPARa and RXRa. Similar results were
also observed with AML12 cells. In the absence of RXRa, no trans-
activation was observed using the Vnn1 promoter (data not
shown). As shown in Fig. 4G, co-transfection of the transcription
factors with a reporter plasmid containing triplicated consensus
PPRE sites in the promoter leads to a detectable luciferase activity
in the presence of PPARa agonists. Furthermore, a signiﬁcant
induction of luciferase activity was observed in the presence of
PPARa agonists when using the 3.5 kB but not the 1kB version of
the Vnn1 promoter in agreement with the bioinformatics predic-
tions. Two candidate PPRE sites were identiﬁed by sequence anal-
ysis (Fig. 4H). We mutated either one or both PPRE sites in the
3.5 kB promoter. As shown in Fig. 4I, in the absence of exogenously
added PPARa agonists, a minimal luciferase activity is detected and
is moderately reduced with mutant promoters. This activity is in-
duced in the presence of agonists but only when using a promoter
containing the functional PPRE sites. The mutation of PPRE1 has
the strongest effect, superior than that of the double mutant. Alto-
gether, these results suggest that the Vnn1 gene is a PPARa-target
gene in liver.
Vnn1 is expressed by centrolobular hepatocytes which are pref-
erentially implicated in lipid and xenobiotic metabolism [32], both
regulated by PPARa activation [30]. These results suggest that
Vnn1 could be an effector of metabolic responses involving PPARa.
Few reports document effects of pantethine [33], a cysteamine pre-
cursor, or pantetheinase inhibitors on lipid metabolism [34]. Cyste-
amine might also act on adiponectin response [35]. However, these
studies are limited by the fact that pantetheinase isoforms can
compensate [11] and that an animal model with total pantethein-
ase deﬁciency is not available. In addition to its catabolic role on
fatty acids, PPARa also regulates cytoprotection, inﬂammation
and hepatocarcinogenesis [36,37], processes also modulated by
Vnn1 [15,16]. Monitoring serum Vnn1 as a reporter of liver PPARa
activity may have a direct interest in hepatocarcinogenesis. Indeed,
chronic exposure of rodents to PPARa agonists results in an in-
crease of tumors [38]. The oncogenic role of PPARa in hepatocytes
is still debated and the differential oncogenic effects of ﬁbrates be-
tween rodents and human might be due to differences in the nat-
ure of PPARa target genes in each species [37]. Therefore, it will be
of interest to test Vnn1 as a marker of PPARa activation in models
of liver damage and cancer and upon ﬁbrate therapy.
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